Shandong Lukang Pharmaceutical Co Ltd
SSE:600789
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Shandong Lukang Pharmaceutical Co Ltd
SSE:600789
|
8.3B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
964.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
572.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
284.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
297.7B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.3B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
227.3B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.1B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.9B USD |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Shandong Lukang Pharmaceutical Co Ltd
Glance View
In the bustling province of Shandong, a prominent player in the pharmaceutical industry, Shandong Lukang Pharmaceutical Co Ltd, traces its roots back to the mid-20th century, embodying the spirit of innovation in healthcare. This enterprise initially embarked on its journey as a penicillin producer, quickly adapting to the shifts in global healthcare demands by expanding its product line to include a broad spectrum of antibiotics, anti-infectives, and other essential medications. With its headquarters strategically located in Jining, Shandong Lukang leverages sophisticated technology and a rich legacy of expertise to manufacture products that cater to both domestic and international markets. The company's revenue streams are a testament to its diversified approach in the pharmaceutical sector. Primarily, Shandong Lukang excels in the research, development, production, and sale of pharmaceuticals, with antibiotics standing at its core. However, the company has adeptly diversified its operations by venturing into the production of veterinary drugs and biochemical products, creating a robust portfolio that ensures steady growth. By maintaining rigorous quality control and a commitment to innovation, it has positioned itself as a reliable supplier in both public and private healthcare sectors, underpinning its financial success through sustained partnerships and strategic market alliances. This solid foundation ensures that Shandong Lukang remains resilient amid the ever-evolving dynamics of the global pharmaceutical landscape.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Shandong Lukang Pharmaceutical Co Ltd is 5%, which is below its 3-year median of 5.3%.
Over the last 3 years, Shandong Lukang Pharmaceutical Co Ltd’s Operating Margin has increased from 3.1% to 5%. During this period, it reached a low of 3.1% on Aug 30, 2022 and a high of 6% on Jun 30, 2024.